SA
Go ProLog In
RXRX
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Hold
10 analysts·Moderate coverage
60
Score
4 Buy (40%)6 Hold (60%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
440%
Hold
660%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$5.50
+87.7%
Consensus
$8.25
+181.6%
Bull
$11.00
+275.4%
12-Month Target Range10 analysts
$5.50$8.25$11.00
Current $2.93Consensus
Current Price
$2.93
Upside to Consensus
$5.32

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+82.14%
EPS—
FY2028
Rev+37.84%
EPS—
FY2029
Rev+61.02%
EPS—

Earnings Surprises

Recent Analyst Actions

May 14, 2026Morgan Stanley
Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley
Target:$5.50
+78.6%from $3.08
Dec 17, 2025UBS
JPMorgan Upgrades Recursion Pharmaceuticals (RXRX ) to Overweight
Target:$11.00
+161.9%from $4.20
Dec 17, 2025Morgan Stanley
JPMorgan Upgrades Recursion Pharmaceuticals (RXRX ) to Overweight
Target:$11.00
+161.9%from $4.20
Feb 28, 2025Leerink Partners
Recursion Pharmaceuticals price target lowered to $6 from $7 at Leerink
Target:$6.00
-20.1%from $7.51
Sep 4, 2024Needham
Recursion Pharmaceuticals (RXRX) PT Lowered to $11 at Needham
Target:$11.00
+80.3%from $6.10
Sep 3, 2024KeyBanc
KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )
Target:$12.00
+97.7%from $6.07
Sep 3, 2024Jefferies
Recursion Pharmaceuticals price target lowered to $6 from $8 at Jefferies
Target:$6.00
-0.3%from $6.02
Jun 26, 2024KeyBanc
KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )
Target:$16.00
+82.6%from $8.76

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance